Related Experiment Video
Updated: Feb 8, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
RALY promotes Epithelial-mesenchymal transition in Hepatocellular carcinoma by regulating Snail
Hee-Won Kim1, Jungsoo Kim2, Jeong-Heon Ko2
1Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea; Korea University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon, 34113, Republic of Korea.
Abstract:
RALY, a heterogeneous nuclear ribonucleoprotein, binds to nascent RNA and participates in multiple aspects of RNA metabolism, including transport, splicing, transcription, and translation. Recent studies have revealed that RALY is overexpressed in various cancers, such as breast, uterine, and liver cancers. This overexpression has been associated with poor patient survival and uncontrolled carcinoma cell proliferation. In this study, we demonstrate that RALY functions as a key regulator of cell proliferation, migration, and invasion in the hepatocellular carcinoma (HCC) cell lines Hep3B and HepG2. Mechanistically, RALY promotes epithelial-mesenchymal transition (EMT) through regulation of the transcription factor Snail. RALY directly binds to Snail mRNA, thereby enhancing its stability. In addition, RALY modulates the TGF-β signaling pathway to promote Snail transcription. Together, our findings establish a functional link between RALY and EMT and reveal a previously unrecognized role of RALY in cancer cell metastasis. Accumulating evidence, including the results presented here, suggests that RALY represents a potential therapeutic target for cancer treatment.
Insights
The heterogeneous nuclear ribonucleoprotein RALY promotes hepatocellular carcinoma (HCC) progression by enhancing cell proliferation, migration, and invasion. RALY targets Snail mRNA to drive epithelial-mesenchymal transition (EMT), suggesting it as a potential cancer therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Metabolism
Background:
- RALY, a heterogeneous nuclear ribonucleoprotein, is involved in RNA metabolism.
- RALY overexpression is linked to poor prognosis in breast, uterine, and liver cancers.
- RALY's role in hepatocellular carcinoma (HCC) remains largely unexplored.
Purpose of the Study:
- To investigate the function of RALY in hepatocellular carcinoma (HCC) cell lines.
- To elucidate the molecular mechanisms by which RALY influences cancer progression.
- To assess RALY as a potential therapeutic target for HCC.
Main Methods:
- Utilized HCC cell lines (Hep3B and HepG2) to study RALY's function.
- Investigated RALY's impact on cell proliferation, migration, and invasion.
- Analyzed RALY's interaction with Snail mRNA and its effect on stability.
- Examined RALY's modulation of the TGF-β signaling pathway.
Main Results:
- RALY significantly regulates proliferation, migration, and invasion in HCC cells.
- RALY directly binds to Snail mRNA, increasing its stability and promoting EMT.
- RALY modulates the TGF-β pathway, further enhancing Snail transcription.
- RALY plays a crucial role in cancer cell metastasis.
Conclusions:
- RALY is a key regulator of cell proliferation and metastasis in HCC.
- RALY promotes EMT by stabilizing Snail mRNA and influencing TGF-β signaling.
- RALY represents a promising therapeutic target for hepatocellular carcinoma treatment.
Related Concept Videos
The Eukaryotic Promoter Region
Cooperative Allosteric Transitions
Phase Transitions
Positive Regulator Molecules
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Properties of Transition Metals

